.jpg?format=webp&width=780)
Vaccination remains the primary measure to prevent the spread of the SARS-CoV-2 virus, necessitating effective licensed vaccines. The QazCovid-in® vaccine was safe over the 6-month monitoring period after two intramuscular immunisations inducing only local short-lived adverse events. The concomitant diseases of participants did not affect the vaccine safety. Two immunisations with the inactivated QazCovid-in® vaccine achieved 82·0% (95% CI 71.1-88.5) protective efficacy against COVID-19 within a 180-day follow-up period.
Like
Save
Share